Italian nationwide survey on pseudomonas aeruginosa from invasive infections: Activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 3, 2018, Pages 664-671

  Giani, Tommaso ^a,b   Arena, Fabio ^a   Pollini, Simona ^a,b   Di Pilato, Vincenzo ^c   D'Andrea, Marco Maria ^a,b   De Angelis, Lucia Henrici ^a   Bassetti, Matteo ^d   Rossolini, Gian Maria ^b,e   Vismara, C ^f   Luzzaro, F ^g   Cavallo, R ^h   Dusi, P A ⁱ   Pagani, E ^j   Sarti, M ^k   Farina, C ^l   Rigoli, R ^m   Scarparo, C ^d   Pecile, W P ^e   Cusi, M G ⁿ   Mencacci, A ^o   Manso, E ^p   Spanu, T ^q   Labonia, M ^r   Tassi, V ^s   Amato, G ^t   Stefani, S ^u   Giraldi, C ^v   Rassu, M ^w   more..

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g A MANZONI HOSPITAL   (Italy)

^h Molinette   (Italy)

ⁱ ASL 1 Imperiese   (Italy)

^j Azienda Sanitaria dell'Alto Adige   (Italy)

^k NOCSAE Hospital   (Italy)

^l PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^m OSPEDALE CA FONCELLO   (Italy)

ⁿ UNIVERSITY HOSPITAL OF SIENA   (Italy)

^o SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^p OSPEDALI RIUNITI   (Italy)

^q FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^r CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^s Policlinico Casarano   (Italy)

^t CARDARELLI HOSPITAL   (Italy)

^u UNIVERSITY OF CATANIA   (Italy)

^v Annunziata Hospital   (Italy)

^w SAN BORTOLO HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BACTERIAL DNA; BACTERIAL ENZYME; BETA LACTAMASE; BETA LACTAMASE GES 5; BETA LACTAMASE IMP; BETA LACTAMASE VIM; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; COLISTIN; GENOMIC DNA; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; TAZOBACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; BROTH DILUTION; CONTROLLED STUDY; GENOME ANALYSIS; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; ITALY; LOWER RESPIRATORY TRACT INFECTION; MIC50; MIC90; MOLECULAR EPIDEMIOLOGY; NONHUMAN; POLYMERASE CHAIN REACTION; POPULATION STRUCTURE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; WHOLE GENOME SEQUENCING; BACTEREMIA; BIOSYNTHESIS; CROSS INFECTION; DRUG EFFECT; ENZYMOLOGY; EPIDEMIOLOGICAL MONITORING; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CEPHALOSPORINS; CROSS INFECTION; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; HUMANS; ITALY; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TAZOBACTAM; WHOLE GENOME SEQUENCING;

EID: 85043350586     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx453     Document Type: Article

References (48)

1. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007; 67: 351-68.
2. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa Clin Microbiol Infect 2005; 11 Suppl 4: 17-32.
3. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-40.
4. Peña C, Suarez C, Tubau F et al. Nosocomial spread of Pseudomonas aeruginosa producing the metallo-β-lactamase VIM-2 in a Spanish hospital:clinical and epidemiological implications. Clin Microbiol Infect 2007; 13: 1026-9.
5. Mesaros N, Nordmann P, Plésiat P et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007; 13: 560-78.
6. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa:clinical impact and complex regulation of chromosomally encoded resistancemechanisms. Clin Microbiol Rev 2009; 22: 582-610.
7. El Zowalaty ME, Al Thani AA, Webster TJ et al. Pseudomonas aeruginosa:arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies. Future Microbiol 2015; 15: 48-24.
8. Oliver A, Mulet X, López-Causapé C et al. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat 2015; 21-22:41-59.
9. Kiser TH, Obritsch MD, Jung R et al. Efflux pump contribution to multidrug resistance in clinical isolates of Pseudomonas aeruginosa. Pharmacotherapy 2010; 30: 632-8.
10. Masuda N, Sakagawa E, Ohya S et al. Substrate specificities of MexABOprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 3322-7.
11. Köhler T, Michea-Hamzehpour M, Epp SF et al. Carbapenem activities against Pseudomonas aeruginosa: respective contributions ofOprD and efflux systems. Antimicrob Agents Chemother 1999; 43: 424-7.
12. Amin El N, Giske CG, Jalal S et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 2005; 113: 187-96.
13. Pai H, Kim J, Lee JH et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001; 45: 480-4.
14. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-86.
15. Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrob Agents Chemother 2009; 54: 24-38.
16. Zhanel GG, Lawson CD, Adam H et al. Ceftazidime-avibactam: a novel cephalosporin/b-lactamase inhibitor combination. Drugs 2013; 73: 159-77.
17. Sader HS, Rhomberg PR, Farrell DJ et al. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 2011; 55: 2390-4.
18. Farrell DJ, Flamm RK, Sader HS et al. Antimicrobial activity of ceftolozanetazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother 2013; 57: 6305-10.
19. Kalil AC, Metersky ML, Klompas M et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society. Clin Infect Dis 2016; 63: 61-111.
20. Jorgensen JH, Pfaller MA, Carrol KC et al. Manual of Clinical Microbiology, 11th edn.Washington, DC: ASM Press, 2015.
21. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Tenth Edition: Approved Standard M07-A10. CLSI, Wayne, PA, USA, 2015.
22. Poirel L, Walsh TR, Cuvillier V et al. Multiplex PCR for detection of acquired carbapenemase genes. DiagnMicrobiol Infect Dis 2011; 70: 119-23.
23. VIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 1999; 43: 1584-90.
24. Sambrook J, MacCallum P, Russell DW. Molecular Cloning: A Laboratory Manual, 3rd edn. New York: Cold Spring Harbor Laboratory Press, 2001.
25. Bankevich A, Nurk S, Antipov D et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 2012; 19: 455-77.
26. Stover CK, Pham XQ, Erwin AL et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000; 406: 959-64.
27. Kaas RS, Leekitcharoenphon P, Aarestrup FM et al. Solving the problemof comparing whole bacterial genomes across different sequencing platforms. PLoS One 2014; 9: e104984-8.
28. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2011; 18: 268-81.
29. Kos VN, Deraspe M, McLaughlin RE et al. The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility. Antimicrob Agents Chemother 2015; 59: 427-36.
30. Berrazeg M, Jeannot K, Yvette V et al. Mutations in β-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins. Antimicrob Agents Chemother 2015; 59: 6248-55.
31. Cabot G, Bruchmann S, Mulet X et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 2014; 58: 3091-9.
32. MacVane SH, Pandey R, Steed LL et al. Emergence of ceftolozanetazobactam resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation. Antimicrob Agents Chemother 2017; doi:10.1128/AAC.01183-17.
33. Grundmann H, Glasner C, Albiger B et al. Occurrence of carbapenemaseproducing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis 2016; 17: 1-11.
34. European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm:ECDC, 2015.
35. Sader HS, Farrell DJ, Castanheira M et al. Antimicrobial activity of ceftolozane/ tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother 2014; 69: 2713-22.
36. Sader HS, Farrell DJ, Flamm RK et al. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intraabdominal and urinary tract infections in European and United States hospitals (2012). J Infect 2014; 69: 266-77.
37. Tato M, García-Castillo M, Bofarull AM et al. In vitro activity of ceftolozane/ tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: results of the CENIT study. Int J Antimicrob Agents 2015; 46: 502-10.
38. Juan C, Zamorano L, Pérez JL et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 2010; 54: 846-51.
39. Walkty A, Karlowsky JA, Adam H et al. In vitro activity of ceftolozanetazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD Study, 2007 to 2012. Antimicrob Agents Chemother 2013; 57: 5707-9.
40. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam:second-generation β-lactam/b-lactamase combinations. Clin Infect Dis 2016; 243-8.
41. Pfaller MA, Shortridge D, Sader HS et al. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015). Braz J Infect Dis 2017; doi:10.1016/j.bjid.2017.06.008.
42. Pfaller MA, Shortridge D, Sader HS et al. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing health care-associated infections in the Asia-pacific region (APAC; minus China, Australia and New Zealand): report from an antimicrobial surveillance program (2013-2015). Int J Antimicrob Agents 2017; doi:10.1016/j. ijantimicag.2017.09.016.
43. Shortridge D, Castanheira M, Pfaller MA et al. Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from U.S. hospitals:report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother 2017; 61: pii=e00465-17.
44. Seifert H, Körber-Irrgang B, Kresken M; German Ceftolozane/Tazobactam Study Group. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. Int J Antimicrob Agents 2017; doi:10.1016/ j.ijantimicag.2017.06.024.
45. Giske CG, Ge J, Nordmann P. Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-β-lactamase-producing Pseudomonas aeruginosa. JAntimicrobChemother 2009; 64: 430-1.
46. Rossolini GM, Luzzaro F, Migliavacca R et al. First countrywide survey of acquired metallo-β-lactamases in gram-negative pathogens in Italy. Antimicrob Agents Chemother 2008; 52: 4023-9.
47. Edelstein MV, Skleenova EN, Shevchenko OV et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis 2013; 13: 867-76.
48. Riera E, Cabot G, Mulet X et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother 2011; 66: 2022-7.